BGI Accuses Illumina of Patent-Related Antitrust Violations (1)

BGI Americas Corp. and two of its subsidiaries advanced their worldwide patent fight over DNA sequencing technology by accusing Illumina Inc. in San Francisco federal court Monday of monopolizing the market through fraudulently obtained patents.

Illumina received a preliminary injunction in June barring the China-based BGI from launching its CoolMPS sequencing system in the U.S., based on the alleged infringement of three Illumina patents related to the use of azidomethyl in DNA sequencing.

The company previously said in a press release that BGI “brazenly copied Illumina’s proprietary sequencing chemistry,” and that Illumina has filed related suits against BGI in Denmark, ...